SOPH Stock Analysis — SOPHIA GENETICS SA (Healthcare >> Health Information Services)
SOPH FAQ
What is SOPH's ROE?
SOPHIA GENETICS SA reports a Return on Equity (ROE) of -177.15%.
What is SOPH's dividend yield?
SOPHIA GENETICS SA offers a dividend yield of 0.00%.
What is SOPH's Quality Score?
Our AI rates SOPH's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SOPH?
Our AI Timing Score for SOPH is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SOPH belong to?
SOPHIA GENETICS SA is classified under the Healthcare >> Health Information Services sector on the NASDAQ exchange
SOPH AI Analysis Summary
Our AI summary for SOPH: SOPHIA GENETICS SA (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 0.00, ROE of -177.15%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.67
Price
-0.09
(-1.56%)
Day Change
|
|
|---|
SOPH, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.67 |
| PBV / Sector |
10.58 / 6.33
|
| Earning Per Share | -0.95 |
| PE / Sector |
N/A / 46.50
|
| PEG or PE/Growth / Sector |
N/A / -0.41
|
| Average 1M Daily Value |
1.75 M
GREAT
|
| Average 1W Daily Value |
0.93 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:30 |
| Symbol | SOPH |
| Name | SOPHIA GENETICS SA |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 83.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 483.24 / 4,079.00 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: La PiEce 12, Rolle, Switzerland, 1180
Phone: 41 21 694 10 60
Website: https://www.sophiagenetics.com
Employees: 415
Description: SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Health Information ServicesAnalysed on the same criteria, ordered by market cap
Google